NCT03033680View on ClinicalTrials.gov

Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

March 24, 2017

Primary Completion Date

January 15, 2021

Study Completion Date

January 15, 2021

Conditions
MSA
Interventions
DRUG

[F-18]PBR06

PET radiopharmaceutical

Trial Locations (1)

02115

Movement Disorders Clinic, 60 Fenwood Road, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT03033680 - Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA | Biotech Hunter | Biotech Hunter